Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Antibodies, Monoclonal"" wg kryterium: Temat


Starter badań:

Tytuł :
Canakinumab improves patient-reported outcomes in children and adults with autoinflammatory recurrent fever syndromes: results from the CLUSTER trial.
Autorzy :
Lachmann HJ; University College London Division of Medicine and Royal Free Hospital, London, UK. .
Lauwerys B; Department of Rheumatology, Cliniques Universitaires Saint-Luc & Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium.
Miettunen P; Department of Paediatric Rheumatology, Alberta Children's Hospital, Calgary, Canada.
Kallinich T; Department of Pneumology and Immunology, Charité Medical University of Berlin, Germany.
Jansson A; Department of Rheumatology and Immunology, Dr. von Hauner Children's Hospital, University Hospital, LMU, Munich, Germany.
Rosner I; Department of Rheumatology, Bnai Zion Medical Center, Haifa, Israel.
Manna R; Department of Internal Medicine and Autoinflammatory Diseases, Fondazione Policlinico Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
Murias S; Paediatric Rheumatology Unit, University Hospital La Paz, Madrid, Spain.
Savic S; Department of Clinical Immunology and Allergy, St James's University Hospital, Leeds, and Musculoskelatal Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, UK.
Smeets S; Immunology, Hepatology and Dermatology Franchise, Novartis Pharma B.V., Arnhem, the Netherlands.
De Benedetti F; Division of Rheumatology, Ospedale Pediatrico Bambino Gesú, Rome, Italy.
Simon A; Department of Internal Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands.
Pokaż więcej
Źródło :
Clinical and experimental rheumatology [Clin Exp Rheumatol] 2021 Sep-Oct; Vol. 39 Suppl 132 (5), pp. 51-58. Date of Electronic Publication: 2021 Oct 06.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Antibodies, Monoclonal*/therapeutic use
Quality of Life*
Adult ; Antibodies, Monoclonal, Humanized ; Child ; Humans ; Patient Reported Outcome Measures ; Syndrome
Czasopismo naukowe
Tytuł :
Early outcomes of migraine after erenumab discontinuation: data from a real-life setting.
Autorzy :
De Matteis E; Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, Via Vetoio, 67100, L'Aquila, Italy.
Affaitati G; Department of Medicine and Science of Aging, 'G. D'Annunzio' University, Chieti, Italy.
Frattale I; Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, Via Vetoio, 67100, L'Aquila, Italy.
Caponnetto V; Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, Via Vetoio, 67100, L'Aquila, Italy.
Pistoia F; Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, Via Vetoio, 67100, L'Aquila, Italy.
Giamberardino MA; Department of Medicine and Science of Aging, 'G. D'Annunzio' University, Chieti, Italy.
Sacco S; Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, Via Vetoio, 67100, L'Aquila, Italy. .
Ornello R; Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, Via Vetoio, 67100, L'Aquila, Italy.
Pokaż więcej
Źródło :
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology [Neurol Sci] 2021 Aug; Vol. 42 (8), pp. 3297-3303. Date of Electronic Publication: 2021 Jan 02.
Typ publikacji :
Journal Article; Multicenter Study
MeSH Terms :
Antibodies, Monoclonal, Humanized*
Migraine Disorders*/drug therapy
Antibodies, Monoclonal/therapeutic use ; Calcitonin Gene-Related Peptide Receptor Antagonists ; Humans
Czasopismo naukowe
Tytuł :
Monoclonal Antibodies During Breastfeeding.
Autorzy :
Anderson PO; Division of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California, USA.
Pokaż więcej
Źródło :
Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine [Breastfeed Med] 2021 Aug; Vol. 16 (8), pp. 591-593. Date of Electronic Publication: 2021 May 05.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Monoclonal*
Breast Feeding*
Antibodies, Monoclonal, Humanized ; Female ; Humans
Czasopismo naukowe
Tytuł :
The Importance of the Timing of Tocilizumab Administration in Moderate to Severely Ill COVID-19: Single Centered Experience Case series.
Autorzy :
Tenda ED; Division of Respirology and Critical Care, Departement of Internal Medicine, Universitas Indonesia. Dr Cipto Mangunkusumo National General Hospital. Imperial College London. .
Andrian S
Albert S
Asaf MM
Pitoyo CW
Setiati S
Subekti I
Pokaż więcej
Źródło :
Acta medica Indonesiana [Acta Med Indones] 2021 Jul; Vol. 53 (3), pp. 319-325.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Antibodies, Monoclonal, Humanized*/administration & dosage
Antibodies, Monoclonal, Humanized*/adverse effects
COVID-19*/diagnosis
COVID-19*/drug therapy
COVID-19*/immunology
COVID-19*/physiopathology
Cytokine Release Syndrome*/etiology
Cytokine Release Syndrome*/immunology
Cytokine Release Syndrome*/prevention & control
Interleukin-6*/antagonists & inhibitors
Interleukin-6*/blood
Time-to-Treatment*
Receptors, Interleukin-6/*immunology
Adult ; Aged ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Drug Monitoring/methods ; Humans ; Male ; Middle Aged ; SARS-CoV-2/isolation & purification ; Severity of Illness Index ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study.
Autorzy :
Zhao Y; Department of Dermatology, Peking University People's Hospital, Beijing 100044, China.
Cai L
Liu XY
Zhang H
Zhang JZ
Pokaż więcej
Źródło :
Chinese medical journal [Chin Med J (Engl)] 2021 May 04; Vol. 134 (11), pp. 1324-1328. Date of Electronic Publication: 2021 May 04.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Monoclonal*/adverse effects
Psoriasis*/drug therapy
Antibodies, Monoclonal, Humanized ; China ; Cohort Studies ; Humans ; Severity of Illness Index ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study).
Autorzy :
Vernieri F; Headache and Neurosonology Unit, Campus Bio-Medico University Hospital, Via Alvaro del Portillo, 200, 00128, Rome, Italy. .
Altamura C; Headache and Neurosonology Unit, Campus Bio-Medico University Hospital, Via Alvaro del Portillo, 200, 00128, Rome, Italy.
Brunelli N; Headache and Neurosonology Unit, Campus Bio-Medico University Hospital, Via Alvaro del Portillo, 200, 00128, Rome, Italy.
Costa CM; Headache and Neurosonology Unit, Campus Bio-Medico University Hospital, Via Alvaro del Portillo, 200, 00128, Rome, Italy.
Aurilia C; Headache and Pain Unit, IRCCS San Raffaele Pisana, Rome, Italy.
Egeo G; Headache and Pain Unit, IRCCS San Raffaele Pisana, Rome, Italy.
Fofi L; Headache and Pain Unit, IRCCS San Raffaele Pisana, Rome, Italy.
Favoni V; IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Pierangeli G; IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Lovati C; Headache Center, Neurology Unit, University Hospital L. Sacco, Milan, Italy.
Aguggia M; Neurology and Stroke Unit, Asti Hospital, Asti, Italy.
d'Onofrio F; Neurology Unit, San Giuseppe Moscati Hospital, Avellino, Italy.
Doretti A; Department of Neurology, Stroke Unit and Laboratory of Neuroscience, Istituto Auxologico Italiano, IRCCS, Milan, Italy.
Di Fiore P; Headache Center, Neurology and Stroke Unit, S. Carlo Borromeo Hospital, Milan, Italy.
Finocchi C; IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Rao R; Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Bono F; Center for Headache and Intracranial Pressure Disorders, Neurology Unit, A.O.U. Mater Domini, Catanzaro, Italy.
Ranieri A; Headache Centre, Neurology and Stroke Unit, A. Cardarelli Hospital, Naples, Italy.
Albanese M; Headache Center, Neurology Unit, Tor Vergata University Hospital, Rome, Italy.; Department of Systems Medicine, Tor Vergata University, Rome, Italy.
Cevoli S; IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Barbanti P; Headache and Pain Unit, IRCCS San Raffaele Pisana, Rome, Italy.; San Raffaele University, Rome, Italy.
Pokaż więcej
Corporate Authors :
GARLIT Study Group
Źródło :
The journal of headache and pain [J Headache Pain] 2021 May 03; Vol. 22 (1), pp. 35. Date of Electronic Publication: 2021 May 03.
Typ publikacji :
Journal Article; Multicenter Study; Observational Study
MeSH Terms :
Antibodies, Monoclonal*
Migraine Disorders*/drug therapy
Migraine Disorders*/prevention & control
Adult ; Antibodies, Monoclonal, Humanized ; Cohort Studies ; Double-Blind Method ; Female ; Humans ; Italy ; Male ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Rituximab hypersensitivity reactions and tolerance of ofatumumab therapy.
Autorzy :
Ali SB; Department of Clinical Immunology and Allergy, Royal Adelaide Hospital, and Department of Immunology, SA Pathology, Adelaide, Australia.
Yuson C; Department of Clinical Immunology and Allergy, Royal Adelaide Hospital, Adelaide, Australia.
Hissaria P; Department of Clinical Immunology and Allergy, Royal Adelaide Hospital, and Department of Immunology, SA Pathology, Adelaide, Australia. .
Pokaż więcej
Źródło :
Clinical and experimental rheumatology [Clin Exp Rheumatol] 2021 May-Jun; Vol. 39 (3), pp. 648-650. Date of Electronic Publication: 2021 Mar 25.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Monoclonal, Humanized*
Antigens, CD20*
Animals ; Antibodies, Monoclonal/adverse effects ; Humans ; Mice ; Rituximab/adverse effects
Czasopismo naukowe
Tytuł :
Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial.
Autorzy :
Bodemer C; Department of Dermatology, Hôpital Necker-Enfants Malades, APHP, Paris, France.
Kaszuba A; DERMED Medical Services, Lodz, Poland.
Kingo K; Tartu University Hospital and University of Tartu, Tartu, Estonia.
Tsianakas A; Fachklinik Bad Bentheim, Bad Bentheim, Germany.
Morita A; Nagoya City University Hospital, Aichi, Japan.
Rivas E; Dermos, Guatemala City, Guatemala.
Papanastasiou P; Novartis Pharma AG, Basel, Switzerland.
Keefe D; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Patekar M; Novartis Pharma AG, Basel, Switzerland.
Charef P; Novartis Pharma AG, Basel, Switzerland.
Zhang L; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Cafoncelli S; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Papavassilis C; Novartis Pharma AG, Basel, Switzerland.
Pokaż więcej
Źródło :
Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2021 Apr; Vol. 35 (4), pp. 938-947. Date of Electronic Publication: 2021 Jan 19.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Antibodies, Monoclonal*/adverse effects
Psoriasis*/drug therapy
Adult ; Antibodies, Monoclonal, Humanized ; Child ; Double-Blind Method ; Humans ; Severity of Illness Index ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial.
Autorzy :
Warren RB; Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester, Manchester, UK.
Carrascosa JM; Department of Dermatology, Germans Trias i Pujol University Hospital (HUGTP), Autonomous University of Barcelona (UAB), Badalona, Spain.
Fumero E; Almirall R&D, Barcelona, Spain.
Schoenenberger A; Almirall R&D, Barcelona, Spain.
Lebwohl MG; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Szepietowski JC; Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.
Reich K; Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, Skinflammation® Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Pokaż więcej
Źródło :
Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2021 Apr; Vol. 35 (4), pp. 919-927. Date of Electronic Publication: 2020 Nov 05.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
MeSH Terms :
Antibodies, Monoclonal*/therapeutic use
Psoriasis*/drug therapy
Adult ; Antibodies, Monoclonal, Humanized ; Humans ; Recurrence ; Severity of Illness Index ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Relationship between serum trough levels and efficacy of brodalumab from a post hoc exploratory analysis of a Japanese study in patients with plaque psoriasis.
Autorzy :
Yamaguchi Y; Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Kanai Y; Medical Affairs, Kyowa Kirin Co., Ltd., Tokyo, Japan.
Kitabayashi H; Medical Affairs, Kyowa Kirin Co., Ltd., Tokyo, Japan.
Okada H; Clinical Sciences Research Laboratories, Translational Research Unit, R&D Division, Kyowa Kirin Co., Ltd., Tokyo, Japan.
Nakagawa H; Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
Pokaż więcej
Źródło :
The Journal of dermatology [J Dermatol] 2021 Mar; Vol. 48 (3), pp. 324-333. Date of Electronic Publication: 2020 Nov 08.
Typ publikacji :
Journal Article; Multicenter Study
MeSH Terms :
Antibodies, Monoclonal*
Psoriasis*/drug therapy
Antibodies, Monoclonal, Humanized ; Humans ; Japan ; Severity of Illness Index ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Two cases of refractory erythrodermic psoriasis effectively treated with secukinumab and a review of the literature.
Autorzy :
Liu LC; Department of Dermatology, The Second Hospital of Jilin University, Changchun, Jilin, China.
Jin XH; Department of Dermatology, The Second Hospital of Jilin University, Changchun, Jilin, China.
Sun C; Department of Dermatology, The Second Hospital of Jilin University, Changchun, Jilin, China.
Xia JX; Department of Dermatology, The Second Hospital of Jilin University, Changchun, Jilin, China.
Pokaż więcej
Źródło :
Dermatologic therapy [Dermatol Ther] 2021 Mar; Vol. 34 (2), pp. e14825. Date of Electronic Publication: 2021 Feb 16.
Typ publikacji :
Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Antibodies, Monoclonal*/therapeutic use
Psoriasis*/diagnosis
Psoriasis*/drug therapy
Adult ; Antibodies, Monoclonal, Humanized ; Female ; Humans ; Male ; Severity of Illness Index ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Mast cell proliferation in the cerebrospinal fluid after intraventricular administration of anti-B7H3 immunotherapy.
Autorzy :
Kramer K; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. .
Donzelli MA; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
Pessin MS; Laboratory Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
Pokaż więcej
Źródło :
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2021 Aug; Vol. 70 (8), pp. 2411-2414. Date of Electronic Publication: 2021 Feb 03.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Antibodies, Monoclonal/*therapeutic use
B7 Antigens/*metabolism
Cell Proliferation/*drug effects
Cerebrospinal Fluid/*drug effects
Mast Cells/*drug effects
Antibodies, Monoclonal, Murine-Derived/therapeutic use ; Cell Proliferation/radiation effects ; Cerebrospinal Fluid/radiation effects ; Child ; Humans ; Immunotherapy/methods ; Iodine Radioisotopes/therapeutic use ; Male ; Mast Cells/radiation effects ; Neuroblastoma/radiotherapy ; Neuroblastoma/therapy ; Radioimmunotherapy/methods
Czasopismo naukowe
Tytuł :
Phage Display Technology as a Powerful Platform for Antibody Drug Discovery.
Autorzy :
Nagano K; Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.; Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.
Tsutsumi Y; Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.; Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.; The Center for Advanced Medical Engineering and Informatics, Osaka University, 1-6, Yamadaoka, Suita, Osaka 565-0871, Japan.
Pokaż więcej
Źródło :
Viruses [Viruses] 2021 Jan 25; Vol. 13 (2). Date of Electronic Publication: 2021 Jan 25.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antibodies, Monoclonal*/immunology
Antibodies, Monoclonal*/metabolism
Antibodies, Monoclonal*/pharmacology
Antibodies, Monoclonal*/therapeutic use
Cell Surface Display Techniques*
Drug Discovery*
Animals ; Antibodies, Monoclonal, Humanized/immunology ; Antibodies, Monoclonal, Humanized/metabolism ; Antibodies, Monoclonal, Humanized/pharmacology ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antibody Affinity ; Autoantibodies/immunology ; High-Throughput Screening Assays ; Humans ; Mice ; Peptide Library
Czasopismo naukowe
Tytuł :
Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action.
Autorzy :
Kast F; Department of Biochemistry, University of Zurich, Zurich, Switzerland.
Schwill M; Department of Biochemistry, University of Zurich, Zurich, Switzerland.; TOLREMO therapeutics AG, Muttenz, Switzerland.
Stüber JC; Department of Biochemistry, University of Zurich, Zurich, Switzerland.; Roche Innovation Center Munich, Penzberg, Germany.
Pfundstein S; Department of Biochemistry, University of Zurich, Zurich, Switzerland.; Zurich Integrative Rodent Physiology (ZIRP), University of Zurich, Zurich, Switzerland.
Nagy-Davidescu G; Department of Biochemistry, University of Zurich, Zurich, Switzerland.
Rodríguez JMM; Laboratory for Animal Model Pathology, Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
Seehusen F; Laboratory for Animal Model Pathology, Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
Richter CP; Department of Biology/Chemistry and Center for Cellular Nanoanalytics, Osnabrück University, Osnabrück, Germany.
Honegger A; Department of Biochemistry, University of Zurich, Zurich, Switzerland.
Hartmann KP; Department of Biochemistry, University of Zurich, Zurich, Switzerland.
Weber TG; Dynamic Biosensors GmbH, Planegg, Germany.
Kroener F; Dynamic Biosensors GmbH, Planegg, Germany.
Ernst P; Department of Biochemistry, University of Zurich, Zurich, Switzerland.; Dean's Office and Coordination Office of the Academic Medicine Zurich, University of Zurich, Zurich, Switzerland.
Piehler J; Department of Biology/Chemistry and Center for Cellular Nanoanalytics, Osnabrück University, Osnabrück, Germany.
Plückthun A; Department of Biochemistry, University of Zurich, Zurich, Switzerland. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2021 Jun 18; Vol. 12 (1), pp. 3790. Date of Electronic Publication: 2021 Jun 18.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Monoclonal/*therapeutic use
Antineoplastic Agents, Immunological/*therapeutic use
Breast Neoplasms/*therapy
Receptor, ErbB-2/*antagonists & inhibitors
Receptor, ErbB-2/*immunology
Animals ; Antibodies, Monoclonal/immunology ; Antibodies, Monoclonal, Humanized/therapeutic use ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Drug Design ; Female ; HeLa Cells ; Humans ; Immunoglobulin G/immunology ; Immunotherapy/methods ; MCF-7 Cells ; Mice ; Mice, SCID ; Trastuzumab/therapeutic use ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Potentiating Antitumor Efficacy Through Radiation and Sustained Intratumoral Delivery of Anti-CD40 and Anti-PDL1.
Autorzy :
Liu HC; Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas.
Viswanath DI; Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas; Texas A&M University, College of Medicine, Bryan, Texas.
Pesaresi F; Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas; Department of Electronics and Telecommunications, Politecnico di Torino, Torino, Italy.
Xu Y; Center for Immunotherapy Research, Houston Methodist Research Institute, Houston, Texas; ImmunoMonitoring Core, Houston Methodist Research Institute, Houston, Texas.
Zhang L; Center for Immunotherapy Research, Houston Methodist Research Institute, Houston, Texas; ImmunoMonitoring Core, Houston Methodist Research Institute, Houston, Texas.
Di Trani N; Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas; University of Chinese Academy of Science (UCAS), Beijing, China.
Paez-Mayorga J; Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas; Tecnologico de Monterrey, School of Medicine and Health Sciences, Monterrey, NL, Mexico.
Hernandez N; Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas.
Wang Y; Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas.
Erm DR; Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas.
Ho J; Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas; Weill Cornell Medical College, Weill Cornell Medicine, New York, New York.
Susnjar A; Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas.
Liu X; Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas.
Demaria S; Weill Cornell Medical College, Weill Cornell Medicine, New York, New York.
Chen SH; Center for Immunotherapy Research, Houston Methodist Research Institute, Houston, Texas; ImmunoMonitoring Core, Houston Methodist Research Institute, Houston, Texas.
Teh BS; Weill Cornell Medical College, Weill Cornell Medicine, New York, New York; Department of Radiation Oncology, Houston Methodist Research Institute, Houston, Texas.
Butler EB; Department of Radiation Oncology, Houston Methodist Research Institute, Houston, Texas.
Xuan Chua CY; Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas. Electronic address: .
Grattoni A; Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas; Department of Radiation Oncology, Houston Methodist Research Institute, Houston, Texas; Department of Surgery, Houston Methodist Research Institute, Houston, Texas. Electronic address: .
Pokaż więcej
Źródło :
International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2021 Jun 01; Vol. 110 (2), pp. 492-506. Date of Electronic Publication: 2020 Aug 05.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal, Humanized/*administration & dosage
Antineoplastic Agents/*administration & dosage
CD40 Antigens/*immunology
Immunotherapy/*methods
Theranostic Nanomedicine/*methods
Triple Negative Breast Neoplasms/*therapy
Animals ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Agents/adverse effects ; B7-H1 Antigen/administration & dosage ; B7-H1 Antigen/immunology ; CD40 Antigens/administration & dosage ; CD8-Positive T-Lymphocytes ; Cell Line, Tumor ; Combined Modality Therapy/methods ; Drug Implants ; Female ; Freeze Drying ; Immunotherapy/adverse effects ; Injections, Intralesional/methods ; Injections, Intraperitoneal ; Liver Neoplasms/secondary ; Lung Neoplasms/secondary ; Mice ; Mice, Inbred BALB C ; Progression-Free Survival ; Radiation Dose Hypofractionation ; Random Allocation ; Response Evaluation Criteria in Solid Tumors ; Treatment Outcome ; Triple Negative Breast Neoplasms/immunology ; Triple Negative Breast Neoplasms/pathology ; Tumor Burden
Czasopismo naukowe
Tytuł :
Exploring antibody repurposing for COVID-19: beyond presumed roles of therapeutic antibodies.
Autorzy :
Rawat P; Protein Bioinformatics Laboratory, Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, Tamil Nadu, 600036, India.
Sharma D; Protein Bioinformatics Laboratory, Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, Tamil Nadu, 600036, India.
Srivastava A; Protein Bioinformatics Laboratory, Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, Tamil Nadu, 600036, India.
Janakiraman V; Infection Biology Lab, Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, Tamil Nadu, 600036, India. .
Gromiha MM; Protein Bioinformatics Laboratory, Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, Tamil Nadu, 600036, India. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2021 May 13; Vol. 11 (1), pp. 10220. Date of Electronic Publication: 2021 May 13.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Repositioning*/methods
Antibodies, Monoclonal/*pharmacology
Antibodies, Neutralizing/*pharmacology
COVID-19/*drug therapy
Antibodies, Monoclonal/immunology ; Antibodies, Monoclonal, Humanized/immunology ; Antibodies, Monoclonal, Humanized/pharmacology ; Antibodies, Neutralizing/immunology ; COVID-19/immunology ; Epitopes/immunology ; Humans ; Ipilimumab/immunology ; Ipilimumab/pharmacology ; Molecular Docking Simulation ; SARS-CoV-2/drug effects ; SARS-CoV-2/immunology ; Spike Glycoprotein, Coronavirus/immunology
Czasopismo naukowe
Tytuł :
Ocular surface disease associated with dupilumab treatment for atopic diseases.
Autorzy :
Utine CA; Department of Ophthalmology, Dokuz Eylul University, Izmir, Turkey; Izmir Biomedicine and Genome Center, Izmir, Turkey.
Li G; The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Asbell P; The Hamilton Eye Institute, The University of Tennessee Health Science Center, Memphis, TN, USA.
Pflugfelder S; Department of Ophthalmology, Baylor College of Medicine, Houston, TX, USA.
Akpek E; The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: .
Pokaż więcej
Źródło :
The ocular surface [Ocul Surf] 2021 Jan; Vol. 19, pp. 151-156. Date of Electronic Publication: 2020 May 18.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antibodies, Monoclonal, Humanized*
Dermatitis, Atopic*/drug therapy
Antibodies, Monoclonal ; Humans ; Interleukin-13
Czasopismo naukowe
Tytuł :
Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials.
Autorzy :
Mazieres J; Institut Universitaire du Cancer de Toulouse, Toulouse University Hospital, Université Paul Sabatier, Toulouse, France. Electronic address: .
Rittmeyer A; Department of Thoracic Oncology, Lungenfachklinik Immenhausen, Immenhausen, Germany.
Gadgeel S; Henry Ford Cancer Institute, Henry Ford Hospital, Detroit, Michigan.
Hida T; Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Gandara DR; Department of Internal Medicine, UC Davis Comprehensive Cancer Center, Sacramento, California.
Cortinovis DL; SC Oncologia Medica, SS Lung Unit Asst Ospedale San Gerardo, Monza, Italy.
Barlesi F; CNRS, INSERM, CRCM, APHM, Aix-Marseille University, Marseille, France.
Yu W; US Medical Affairs, Genentech, Inc., South San Francisco, California.
Matheny C; Product Development, Oncology, Genentech, Inc., South San Francisco, California.
Ballinger M; Product Development, Oncology, Genentech, Inc., South San Francisco, California.
Park K; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Pokaż więcej
Źródło :
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2021 Jan; Vol. 16 (1), pp. 140-150. Date of Electronic Publication: 2020 Nov 06.
Typ publikacji :
Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal*
Docetaxel*
Lung Neoplasms*/drug therapy
Antibodies, Monoclonal, Humanized ; Humans
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies